Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Claudio Borghi

Showing results (21-30 of 613) with videos related to

Pageof 62
Sort By:
Giornale Italiano Di Cardiologia (2006)|May 17, 2022
[New evidence on coffee consumption, hypertension and cardiovascular diseases]Claudio Borghi, Alessio Bragagni
Journal of Hypertension|December 20, 2007
Central blood pressure as estimate of cardiovascular risk: potentials and limitationsGuido Grassi, Claudio Borghi
Current Opinion in Cardiology|March 30, 2019
Hyperuricaemia and vascular risk: the debate continuesMatteo Landolfo, Claudio Borghi
Patient Preference and Adherence|July 14, 2012
Fixed combination of lercanidipine and enalapril in the management of hypertension: focus on patient preference and adherenceClaudio Borghi, Francesca Santi
European Heart Journal Supplements : Journal of the European Society of Cardiology|November 16, 2022
'Use of lipid-lowering therapy: the guidelines, the drugs or the patient?'Claudio Borghi, Alessio Bragagni
European Journal of Internal Medicine|August 7, 2025
Uric acid and heart failure with mildly reduced ejection fraction (HFmrEF): one more stepClaudio Borghi, Giulia Fiorini
Giornale Italiano Di Cardiologia (2006)|June 18, 2016
[The new lipid-lowering drugs: focus on monoclonal antibodies]Claudio Borghi, Claudio Cimminiello
Hypertension (Dallas, Tex. : 1979)|February 12, 2016
Urate-Lowering Drugs and Prevention of Cardiovascular Disease: The Emerging Role of Xanthine Oxidase InhibitionClaudio Borghi, Giovambattista Desideri
European Heart Journal Supplements : Journal of the European Society of Cardiology|June 12, 2020
Who needs acetylsalicylic acid? Some order after many studiesClaudio Borghi, Fulvio Ventura
European Heart Journal Supplements : Journal of the European Society of Cardiology|April 24, 2023
Clinical results and mechanism of action of icosapent ethylClaudio Borghi, Alessio Bragagni
Pageof 62

Showing results (21-30 of 613) with videos related to

Sort By:
Pageof 62
Giornale Italiano Di Cardiologia (2006)|May 17, 2022
[New evidence on coffee consumption, hypertension and cardiovascular diseases]Claudio Borghi, Alessio Bragagni
Journal of Hypertension|December 20, 2007
Central blood pressure as estimate of cardiovascular risk: potentials and limitationsGuido Grassi, Claudio Borghi
Current Opinion in Cardiology|March 30, 2019
Hyperuricaemia and vascular risk: the debate continuesMatteo Landolfo, Claudio Borghi
Patient Preference and Adherence|July 14, 2012
Fixed combination of lercanidipine and enalapril in the management of hypertension: focus on patient preference and adherenceClaudio Borghi, Francesca Santi
European Heart Journal Supplements : Journal of the European Society of Cardiology|November 16, 2022
'Use of lipid-lowering therapy: the guidelines, the drugs or the patient?'Claudio Borghi, Alessio Bragagni
European Journal of Internal Medicine|August 7, 2025
Uric acid and heart failure with mildly reduced ejection fraction (HFmrEF): one more stepClaudio Borghi, Giulia Fiorini
Giornale Italiano Di Cardiologia (2006)|June 18, 2016
[The new lipid-lowering drugs: focus on monoclonal antibodies]Claudio Borghi, Claudio Cimminiello
Hypertension (Dallas, Tex. : 1979)|February 12, 2016
Urate-Lowering Drugs and Prevention of Cardiovascular Disease: The Emerging Role of Xanthine Oxidase InhibitionClaudio Borghi, Giovambattista Desideri
European Heart Journal Supplements : Journal of the European Society of Cardiology|June 12, 2020
Who needs acetylsalicylic acid? Some order after many studiesClaudio Borghi, Fulvio Ventura
European Heart Journal Supplements : Journal of the European Society of Cardiology|April 24, 2023
Clinical results and mechanism of action of icosapent ethylClaudio Borghi, Alessio Bragagni
Pageof 62